Expression Pattern and Prognostic Value of EPHA/EFNA in Breast Cancer by Bioinformatics Analysis: Revealing Its Importance in Chemotherapy

Table 3

Prognostic value of EPHA/EFNA mRNA expression for RFS in BrCa patients undergoing chemotherapy.

Chemotherapies	Cases of RFS	HR	95% CI	value
EPHA1
Adjuvant chemotherapy	594	1.28	0.94–1.73	0.11
Neoadjuvant chemotherapy	223	0.39	0.22–0.68	<0.001
Nonchemotherapy	1,873	0.82	0.69–0.97	0.023
EPHA2
Adjuvant chemotherapy	594	1.49	1.08–2.06	0.016
Neoadjuvant chemotherapy	223	0.55	0.31–0.97	0.037
Nonchemotherapy	1,873	0.8	0.66–0.98	0.029
EPHA3
Adjuvant chemotherapy	594	1.55	1.12–2.15	0.008
Neoadjuvant chemotherapy	223	1.95	1–3.8	0.048
Nonchemotherapy	1,873	0.71	0.58–0.87	0.001
EPHA4
Adjuvant chemotherapy	255	1.95	1.2–3.18	0.0064
Neoadjuvant chemotherapy	111	0.76	0.35–1.65	0.48
Nonchemotherapy	243	1.57	0.91–2.71	0.1
EPHA5
Adjuvant chemotherapy	255	0.43	0.25–0.93	0.002
Neoadjuvant chemotherapy	111	0.34	0.16–0.77	0.004
Nonchemotherapy	243	0.69	0.39–1.22	0.2
EPHA6
Adjuvant chemotherapy	255	0.51	0.27–0.95	0.03
Neoadjuvant chemotherapy	111	1.9	0.9–3.99	0.086
Nonchemotherapy	243	0.7	0.39–1.24	0.22
EPHA7
Adjuvant chemotherapy	255	0.64	0.4–1.03	0.065
Neoadjuvant chemotherapy	111	1.86	0.82–4.23	0.13
Nonchemotherapy	243	1.42	0.82–2.46	0.21
EPHA10
Adjuvant chemotherapy	255	0.48	0.29–0.8	0.0043
Neoadjuvant chemotherapy	111	2.43	1.16–5.9	0.016
Nonchemotherapy	243	0.62	0.35–1.11	0.1
EFNA1
Adjuvant chemotherapy	594	0.82	0.6–1.11	0.2
Neoadjuvant chemotherapy	223	0.73	0.42–1.26	0.25
Nonchemotherapy	1,873	0.82	0.69–0.97	0.02
EFNA3
Adjuvant chemotherapy	594	1.96	1.44–2.65	<0.001
Neoadjuvant chemotherapy	223	1.34	0.77–2.32	0.3
Nonchemotherapy	1,873	1.2	1–1.44	0.05
EFNA4
Adjuvant chemotherapy	594	1.4	1.02–1.93	0.037
Neoadjuvant chemotherapy	223	0.71	0.41–1.23	0.22
Nonchemotherapy	1,873	0.86	0.73–1.02	0.077
EFNA5
Adjuvant chemotherapy	594	0.85	0.6–1.19	0.34
Neoadjuvant chemotherapy	223	0.63	0.35–1.14	0.12
Nonchemotherapy	1,873	0.78	0.64–0.95	0.012